Federal

The Federal Circuit vacated a multi-million dollar patent damages award against Chilisin Electronics, holding that the district court abused its discretion by admitting a damages expert opinion that failed to differentiate between infringing and non-infringing products in the royalty base calculatio

The Federal Circuit partially affirmed and partially vacated PTAB’s obviousness rulings on Corephotonics dual-aperture camera patents, holding that one prior art reference was analogous on substantial evidence but remanding for the Board to explain whether a second reference meets the analogou

The Federal Circuit vacated an invalidity judgment against Finjan’s cybersecurity patents that had been based on collateral estoppel from a since-vacated case, while affirming non-infringement on claim construction grounds and excluding Finjan’s damages expert for inadequate apportionmen

The Federal Circuit held that the PTAB erred in categorically excluding expert testimony on the structure of computer-implemented means-plus-function claim limitations when the specification identifies named software protocols, clarifying a two-track framework for evaluating such claims.

The Federal Circuit affirmed PTAB’s obviousness finding for radiosurgery patents, clarifying that a reasonable expectation of success does not require an explicit separate finding and may be implicit in a well-supported motivation-to-combine analysis.

The Federal Circuit held that the PTAB applied an unduly strict standard when it rejected Netflix’s analogous art argument in an IPR, ruling that petitioners need not perfectly articulate the ‘field of endeavor’ in magic words—what matters is whether the prior art reference and the

The Federal Circuit affirmed PTAB’s denial of a motion to amend patent claims in IPR, holding that proposed substitute claims were broader than original claims in at least some respects, and that claims broader in any respect cannot be substituted regardless of narrowing in others.

In a precedent-setting decision, the Federal Circuit held that patent term adjustments granted due to USPTO prosecution delays do not protect a later-expiring patent from obviousness-type double patenting challenges based on an earlier-expiring family member.

The Federal Circuit vacated the PTAB’s finding that Volvo Penta’s stern drive patent was obvious, holding that the Board improperly dismissed evidence of secondary considerations—including copying, commercial success, and industry praise—when competitors’ own recognition that the p

The Federal Circuit affirmed that IPR petitioner reply arguments expanding on cost and time savings as a motivation to combine were not impermissibly new—they properly responded to the patent owner’s opposition and were a fair extension of the efficiency rationale raised in the original petiti

The Federal Circuit vacated two PTAB decisions, holding that when a patent owner introduces a new claim construction for the first time in its post-institution response, the petitioner must be given a fair opportunity to introduce new arguments and evidence under that construction in its reply.

The Federal Circuit affirmed that United Therapeutics’ patents covering inhaled treprostinil for pulmonary hypertension satisfy enablement and written description requirements, holding that method-of-treatment claims need not separately address every disease variant in the specification.

The Federal Circuit held that patents governed exclusively by the America Invents Act cannot be drawn into interference proceedings—a landmark ruling that clarifies the divide between the old first-to-invent system and the modern first-inventor-to-file regime.

The Federal Circuit affirmed rejection of a reissue patent application that tried to broaden claims beyond the original patent’s single disclosed embodiment, holding that reissue claims must be directed to the same invention explicitly described in the original patent—not to undisclosed altern

The Federal Circuit vacated the PTAB’s IPR decisions upholding Medtronic’s sacral nerve stimulation patents, finding the Board committed a fundamental error by limiting the motivation-to-combine inquiry to the specific application context of the primary reference rather than the full cla

The Federal Circuit reversed the dismissal of an induced patent infringement suit on res judicata grounds, holding that a prior judgment on direct infringement claims does not preclude a subsequent suit for induced infringement when the induced infringement claims are based on different operative fa

The Federal Circuit affirmed PTAB’s holding that Medytox’s botulinum toxin patents were not enabled across their full claimed scope, and clarified that PTAB preliminary guidance under the motion-to-amend pilot program is non-binding.

The Federal Circuit affirmed rejection of a patent application covering a hypertension treatment method, holding that discovering an unexpected mechanism through which known drugs achieve a known result does not overcome a prima facie obviousness case rooted in inherency.

The Federal Circuit affirmed PTAB’s decision to disregard Parus Holdings’ evidence in IPR proceedings, holding that a patent owner’s attempt to incorporate arguments by reference through voluminous exhibits violates PTAB procedural rules and the APA does not require the Board to ov

The Federal Circuit affirmed that a nonparty who shared key design elements for an expandable hose with the named inventor at a pre-filing meeting was a co-inventor who should have been listed on the patents, and that his testimony was adequately corroborated by physical prototypes and documentary e

The Federal Circuit reversed the PTAB’s reliance on commercial success as a secondary consideration of nonobviousness for car floor mat patents, holding that evidence of commercial success must be linked to the claimed combination as a whole, not to a single feature that was already present in